| Heading: |
Medical Treatments and Tofersen |
| Question ID: |
1803845 |
| UIN: |
53047 |
| House: |
Commons |
| Date tabled: |
2025-05-19 |
| Asking Member ID: |
4131 |
| Asking Member display name: |
Jim Shannon
|
| Asking Member handle: |
jimshannonmp
|
| Asking Member Twitter reference: |
@jimshannonmp
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential impact of Early Access Programmes on equity of access to (a) tofersen and (b) other innovative treatments. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-05-27 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Early access schemes for unlicenced medicines, where approval may be obtained in other markets, including where a licence exists but a National Institute for Health and Care Excellence decision is not available, are managed by companies to benefit patient... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |